Company: CDT
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001246
Chunk: 12

Company: CDT Equity Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 1A
Chunk 12
---
 financial statements. Our internal control over financial reporting will not prevent or detect all errors
and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that
the control system’s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls
can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud
will be detected.

If
we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act in a timely manner, or if we are unable to maintain
proper and effective internal controls, we may not be able to produce timely and accurate financial statements. If we cannot provide
reliable financial reports or prevent fraud, our business and results of operations could be harmed, investors could lose confidence
in our reported financial information, and we could be subject to sanctions or investigations by Nasdaq, the SEC, or other regulatory
authorities.

If
we do not develop and implement all required accounting practices and policies, we may be unable to provide the financial information
required of a U.S. publicly traded company in a timely and reliable manner.

If
we fail to develop and maintain effective internal controls and procedures and disclosure procedures and controls, we may be unable to
provide financial information and required SEC reports that a U.S. publicly traded company is required to provide in a timely and reliable
fashion. Any such delays or deficiencies could penalize us, including by limiting our ability to obtain financing, either in the public
capital markets or from private sources and hurt our reputation and could thereby impede our ability to implement our growth strategy.
In addition, any such delays or deficiencies could result in our failure to meet the requirements for continued listing of our shares
of common stock on a national securities exchange.

We
may face product liability exposure, and if successful claims are brought against us, we may incur substantial liability if our insurance
coverage for those claims is inadequate.

We
face an inherent risk of product liability as a result of the clinical testing of our clinical assets and will face an even greater risk
if we commercialize any products. This risk exists even if a product is approved for commercial sale by the FDA and manufactured in facilities
licensed and regulated by the FDA or an applicable foreign regulatory authority. Our products and clinical assets are designed to affect
important bodily functions and processes. Any side effects, manufacturing defects, misuse, or abuse